Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bayer AG is a German-based life science company. The Company's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on seeds, improved plant traits, chemical and biological crop protection products, digital solutions and customer service for sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others.

  • Revenue in EUR (TTM)47.64bn
  • Net income in EUR-2.94bn
  • Incorporated1952
  • Employees99.72k
  • Location
    Bayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
  • Phone+49 214301
  • Fax+49 2 143066328
  • Websitehttps://www.bayer.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sandoz Group AG-102.27bn-102.27bn13.54bn23.85k------------------------------------------------7.23---90.92------
Genmab A/S2.21bn583.55m17.48bn2.20k29.864.08--7.9266.0566.05249.95483.850.5037--3.097,474,592.0013.3117.4314.2518.5955.82--26.4235.8713.32--0.0238--13.5740.35-20.1824.21-4.66--
argenx SE1.15bn-275.83m20.80bn1.15k--5.41--18.14-4.81-4.8120.1164.710.31950.43733.72998,614.30-7.69-17.65-8.49-19.7990.39---24.06-97.729.01--0.0049--198.56117.2558.42--122.32--
UCB SA5.25bn343.00m23.50bn9.08k68.622.5522.724.471.761.7626.9147.300.33451.764.63578,223.102.185.032.676.2867.5072.216.5312.660.92243.140.252936.44-4.802.54-18.33-15.41-1.512.36
Bayer AG47.64bn-2.94bn26.50bn99.72k--0.80473.550.5562-2.99-2.9948.4933.520.39511.434.85477,693.20-2.44-1.79-3.34-2.3858.5459.02-6.18-4.800.80153.400.5764---6.115.33-170.87--1.19-47.66
HALEON PLC13.20bn1.23bn35.16bn24.00k29.211.8349.022.660.11280.11281.221.800.32823.155.76470,916.703.23--3.73--61.59--9.83--0.73497.370.3611--4.09---1.04------
Data as of Apr 26 2024. Currency figures normalised to Bayer AG's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.